Lonza Group AG
SIX:LONN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
325
587.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Lonza Group AG
Lonza Group AG
Cash from Investing Activities
Lonza Group AG
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lonza Group AG
SIX:LONN
|
Cash from Investing Activities
-CHf1.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-27%
|
|
|
Bachem Holding AG
SIX:BANB
|
Cash from Investing Activities
-CHf228.5m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-44%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Cash from Investing Activities
-CHf138.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Tecan Group AG
SIX:TECN
|
Cash from Investing Activities
-CHf70.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Cash from Investing Activities
-€59.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Cash from Investing Activities
-CHf17.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Lonza Group AG
Glance View
Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biologics, Lonza stands out for its extensive technological capabilities and state-of-the-art facilities, positioning itself at the forefront of an industry that is rapidly transforming healthcare. For investors seeking to understand Lonza's value proposition, it’s essential to appreciate the company's robust financial performance and strategic growth initiatives. Lonza has consistently demonstrated strong revenue growth, driven by its diversified portfolio and a commitment to research and development. The company has made significant investments in expanding its global manufacturing footprint, notably through the integration of advanced technology for efficient production processes. Furthermore, Lonza's strategic collaborations with major pharmaceutical enterprises in cell and gene therapies highlight its potential for sustained growth. As the world increasingly emphasizes innovation in the healthcare sector, Lonza Group AG remains well-poised to capitalize on emerging opportunities, making it an attractive prospect for investors looking to tap into the growing life sciences market.
See Also
What is Lonza Group AG's Cash from Investing Activities?
Cash from Investing Activities
-1.7B
CHF
Based on the financial report for Jun 30, 2024, Lonza Group AG's Cash from Investing Activities amounts to -1.7B CHF.
What is Lonza Group AG's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-27%
Over the last year, the Cash from Investing Activities growth was -39%. The average annual Cash from Investing Activities growth rates for Lonza Group AG have been -18% over the past three years , -55% over the past five years , and -27% over the past ten years .
You don't have any saved screeners yet
